Skip to main content
PMC home page
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1996 Aug;149(2):469–481.

CD30 ligand expression in nonmalignant and Hodgkin's disease-involved lymphoid tissues.

H J Gruss 1, A Pinto 1, A Gloghini 1, E Wehnes 1, B Wright 1, N Boiani 1, D Aldinucci 1, V Gattei 1, V Zagonel 1, C A Smith 1, M E Kadin 1, C von Schilling 1, R G Goodwin 1, F Herrmann 1, A Carbone 1
PMCID: PMC1865328  PMID: 8701986

Abstract

The CD30 ligand (CD30L) is a type II transmembrane glycoprotein of the tumor necrosis factor ligand superfamily. Recent cloning of CD30L has enabled studies to explore its function and tissue distribution. For instance, recombinant CD30L has been shown to co-stimulate T cells and to act as mitogen for Hodgkin's disease (HD)-derived cell lines. The counter-receptor for CD30L, ie, CD30, is a type I cytokine receptor that is highly expressed by activated T cells, Hodgkin and Reed-Sternberg (H-RS) cells, and anaplastic large cell lymphoma cells. In the present study, recombinant membrane-bound and soluble human CD30L were instrumental to raise a monoclonal antibody (M80) recognizing membrane-bound CD30L on transfected and native cells. With this reagent, a panel of cultured lymphoma-derived cell lines as well as primary normal, reactive, and HD-involved lymphoid tissues were examined for expression of CD30L by immunostaining and flow cytometry. In reactive lymphnodes and tonsils, CD30L was expressed by a small subset of lymphoid cells, histiocytes, and granulocytes. Higher levels of CD30L expression were noted in HD lesions among bystander cells; ie, T cells and granulocytes that surrounded H-RS cells. Native CD30L displayed at the cell surface was functionally active as shown by the ability of fixed granulocytes to interact with CD30+ cell lines. Moreover, CD30L was detectable, although to a lower staining intensity, in primary H-RS cells of all HD tissues investigated regardless of the histological subtype and the phenotype of H-RS cells (ie, CD30+/CD40+ versus CD30-/CD40+). Co-expression of CD30 and CD30L that was seen on H-RS cells of all, except the CD30- nodular lymphocyte predominant, subtypes of HD may point to the use of this pair of molecules in paracrine and/or autocrine mitogenic cell interactions. Monoclonal antibody M80 may thus represent a useful tool for studying CD30L expression on cultured cell lines and primary cells from normal, reactive, and malignant tissues.

Full text

PDF
469

Images in this article

475Figure 2
on p.475
476Figure 3
on p.476
477Figure 4
on p.477
477Figure 5
on p.477

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alzona M., Jäck H. M., Fisher R. I., Ellis T. M. CD30 defines a subset of activated human T cells that produce IFN-gamma and IL-5 and exhibit enhanced B cell helper activity. J Immunol. 1994 Oct 1;153(7):2861–2867. [PubMed] [Google Scholar]
  2. Alzona M., Jäck H. M., Fisher R. I., Ellis T. M. IL-12 activates IFN-gamma production through the preferential activation of CD30+ T cells. J Immunol. 1995 Jan 1;154(1):9–16. [PubMed] [Google Scholar]
  3. Andreesen R., Osterholz J., Löhr G. W., Bross K. J. A Hodgkin cell-specific antigen is expressed on a subset of auto- and alloactivated T (helper) lymphoblasts. Blood. 1984 Jun;63(6):1299–1302. [PubMed] [Google Scholar]
  4. Armitage R. J., Beckmann M. P., Idzerda R. L., Alpert A., Fanslow W. C. Regulation of interleukin 4 receptors on human T cells. Int Immunol. 1990;2(11):1039–1045. doi: 10.1093/intimm/2.11.1039. [DOI] [PubMed] [Google Scholar]
  5. Armitage R. J. Tumor necrosis factor receptor superfamily members and their ligands. Curr Opin Immunol. 1994 Jun;6(3):407–413. doi: 10.1016/0952-7915(94)90119-8. [DOI] [PubMed] [Google Scholar]
  6. Banchereau J., Bazan F., Blanchard D., Brière F., Galizzi J. P., van Kooten C., Liu Y. J., Rousset F., Saeland S. The CD40 antigen and its ligand. Annu Rev Immunol. 1994;12:881–922. doi: 10.1146/annurev.iy.12.040194.004313. [DOI] [PubMed] [Google Scholar]
  7. Brattig N. W., Medina-De la Garza C. E., Tischendorf F. W. Comparative study of eosinophil purification on Nycodenz, Metrizamide and Percoll density gradients. Eur J Haematol. 1987 Aug;39(2):148–153. doi: 10.1111/j.1600-0609.1987.tb00745.x. [DOI] [PubMed] [Google Scholar]
  8. Carbone A., Gloghini A., Gattei V., Aldinucci D., Degan M., De Paoli P., Zagonel V., Pinto A. Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines. Blood. 1995 Feb 1;85(3):780–789. [PubMed] [Google Scholar]
  9. Carbone A., Gloghini A., Gruss H. J., Pinto A. CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin's disease. Am J Pathol. 1995 Oct;147(4):912–922. [PMC free article] [PubMed] [Google Scholar]
  10. Carbone A., Gloghini A., Volpe R. Paraffin section immunohistochemistry in the diagnosis of Hodgkin's disease and anaplastic large cell (CD30+) lymphomas. Virchows Arch A Pathol Anat Histopathol. 1992;420(6):527–532. doi: 10.1007/BF01600258. [DOI] [PubMed] [Google Scholar]
  11. Cordell J. L., Falini B., Erber W. N., Ghosh A. K., Abdulaziz Z., MacDonald S., Pulford K. A., Stein H., Mason D. Y. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem. 1984 Feb;32(2):219–229. doi: 10.1177/32.2.6198355. [DOI] [PubMed] [Google Scholar]
  12. Del Prete G., De Carli M., Almerigogna F., Daniel C. K., D'Elios M. M., Zancuoghi G., Vinante F., Pizzolo G., Romagnani S. Preferential expression of CD30 by human CD4+ T cells producing Th2-type cytokines. FASEB J. 1995 Jan;9(1):81–86. [PubMed] [Google Scholar]
  13. Delabie J., Ceuppens J. L., Vandenberghe P., de Boer M., Coorevits L., De Wolf-Peeters C. The B7/BB1 antigen is expressed by Reed-Sternberg cells of Hodgkin's disease and contributes to the stimulating capacity of Hodgkin's disease-derived cell lines. Blood. 1993 Nov 1;82(9):2845–2852. [PubMed] [Google Scholar]
  14. Drexler H. G. Recent results on the biology of Hodgkin and Reed-Sternberg cells. I. Biopsy material. Leuk Lymphoma. 1992 Nov;8(4-5):283–313. doi: 10.3109/10428199209051008. [DOI] [PubMed] [Google Scholar]
  15. Dürkop H., Latza U., Hummel M., Eitelbach F., Seed B., Stein H. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell. 1992 Feb 7;68(3):421–427. doi: 10.1016/0092-8674(92)90180-k. [DOI] [PubMed] [Google Scholar]
  16. Ellis T. M., Simms P. E., Slivnick D. J., Jäck H. M., Fisher R. I. CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+ T cells. J Immunol. 1993 Sep 1;151(5):2380–2389. [PubMed] [Google Scholar]
  17. Falini B., Pileri S., Pizzolo G., Dürkop H., Flenghi L., Stirpe F., Martelli M. F., Stein H. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood. 1995 Jan 1;85(1):1–14. [PubMed] [Google Scholar]
  18. Fanslow W. C., Anderson D. M., Grabstein K. H., Clark E. A., Cosman D., Armitage R. J. Soluble forms of CD40 inhibit biologic responses of human B cells. J Immunol. 1992 Jul 15;149(2):655–660. [PubMed] [Google Scholar]
  19. Gauchat J. F., Henchoz S., Mazzei G., Aubry J. P., Brunner T., Blasey H., Life P., Talabot D., Flores-Romo L., Thompson J. Induction of human IgE synthesis in B cells by mast cells and basophils. Nature. 1993 Sep 23;365(6444):340–343. doi: 10.1038/365340a0. [DOI] [PubMed] [Google Scholar]
  20. Gruss H-J, Herrmann F. CD30 ligand, a member of the TNF ligand superfamily, with growth and activation control CD30+ lymphoid and lymphoma cells. Leuk Lymphoma. 1996 Feb;20(5-6):397–409. doi: 10.3109/10428199609052421. [DOI] [PubMed] [Google Scholar]
  21. Gruss H. J., Boiani N., Williams D. E., Armitage R. J., Smith C. A., Goodwin R. G. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood. 1994 Apr 15;83(8):2045–2056. [PubMed] [Google Scholar]
  22. Gruss H. J., DaSilva N., Hu Z. B., Uphoff C. C., Goodwin R. G., Drexler H. G. Expression and regulation of CD30 ligand and CD30 in human leukemia-lymphoma cell lines. Leukemia. 1994 Dec;8(12):2083–2094. [PubMed] [Google Scholar]
  23. Gruss H. J., Dower S. K. Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. Blood. 1995 Jun 15;85(12):3378–3404. [PubMed] [Google Scholar]
  24. Gruss H. J., Hirschstein D., Wright B., Ulrich D., Caligiuri M. A., Barcos M., Strockbine L., Armitage R. J., Dower S. K. Expression and function of CD40 on Hodgkin and Reed-Sternberg cells and the possible relevance for Hodgkin's disease. Blood. 1994 Oct 1;84(7):2305–2314. [PubMed] [Google Scholar]
  25. Gruss H. J., Ulrich D., Braddy S., Armitage R. J., Dower S. K. Recombinant CD30 ligand and CD40 ligand share common biological activities on Hodgkin and Reed-Sternberg cells. Eur J Immunol. 1995 Jul;25(7):2083–2089. doi: 10.1002/eji.1830250742. [DOI] [PubMed] [Google Scholar]
  26. Hecht T. T., Longo D. L., Cossman J., Bolen J. B., Hsu S. M., Israel M., Fisher R. I. Production and characterization of a monoclonal antibody that binds Reed-Sternberg cells. J Immunol. 1985 Jun;134(6):4231–4236. [PubMed] [Google Scholar]
  27. Herbst H., Stein H., Niedobitek G. Epstein-Barr virus and CD30+ malignant lymphomas. Crit Rev Oncog. 1993;4(2):191–239. [PubMed] [Google Scholar]
  28. Hsu S. M., Raine L., Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981 Apr;29(4):577–580. doi: 10.1177/29.4.6166661. [DOI] [PubMed] [Google Scholar]
  29. Kadin M. E. Pathology of Hodgkin's disease. Curr Opin Oncol. 1994 Sep;6(5):456–463. doi: 10.1097/00001622-199409000-00002. [DOI] [PubMed] [Google Scholar]
  30. Lane P., Traunecker A., Hubele S., Inui S., Lanzavecchia A., Gray D. Activated human T cells express a ligand for the human B cell-associated antigen CD40 which participates in T cell-dependent activation of B lymphocytes. Eur J Immunol. 1992 Oct;22(10):2573–2578. doi: 10.1002/eji.1830221016. [DOI] [PubMed] [Google Scholar]
  31. Manetti R., Annunziato F., Biagiotti R., Giudizi M. G., Piccinni M. P., Giannarini L., Sampognaro S., Parronchi P., Vinante F., Pizzolo G. CD30 expression by CD8+ T cells producing type 2 helper cytokines. Evidence for large numbers of CD8+CD30+ T cell clones in human immunodeficiency virus infection. J Exp Med. 1994 Dec 1;180(6):2407–2411. doi: 10.1084/jem.180.6.2407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. McMahan C. J., Slack J. L., Mosley B., Cosman D., Lupton S. D., Brunton L. L., Grubin C. E., Wignall J. M., Jenkins N. A., Brannan C. I. A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types. EMBO J. 1991 Oct;10(10):2821–2832. doi: 10.1002/j.1460-2075.1991.tb07831.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Munro J. M., Freedman A. S., Aster J. C., Gribben J. G., Lee N. C., Rhynhart K. K., Banchereau J., Nadler L. M. In vivo expression of the B7 costimulatory molecule by subsets of antigen-presenting cells and the malignant cells of Hodgkin's disease. Blood. 1994 Feb 1;83(3):793–798. [PubMed] [Google Scholar]
  34. Pinto A., Gloghini A., Gattei V., Aldinucci D., Zagonel V., Carbone A. Expression of the c-kit receptor in human lymphomas is restricted to Hodgkin's disease and CD30+ anaplastic large cell lymphomas. Blood. 1994 Feb 1;83(3):785–792. [PubMed] [Google Scholar]
  35. Poppema S. The nature of the lymphocytes surrounding Reed-Sternberg cells in nodular lymphocyte predominance and in other types of Hodgkin's disease. Am J Pathol. 1989 Aug;135(2):351–357. [PMC free article] [PubMed] [Google Scholar]
  36. Ruco L. P., Pomponi D., Pigott R., Gearing A. J., Baiocchini A., Baroni C. D. Expression and cell distribution of the intercellular adhesion molecule, vascular cell adhesion molecule, endothelial leukocyte adhesion molecule, and endothelial cell adhesion molecule (CD31) in reactive human lymph nodes and in Hodgkin's disease. Am J Pathol. 1992 Jun;140(6):1337–1344. [PMC free article] [PubMed] [Google Scholar]
  37. Sanders M. E., Makgoba M. W., Sussman E. H., Luce G. E., Cossman J., Shaw S. Molecular pathways of adhesion in spontaneous rosetting of T-lymphocytes to the Hodgkin's cell line L428. Cancer Res. 1988 Jan 1;48(1):37–40. [PubMed] [Google Scholar]
  38. Schwab U., Stein H., Gerdes J., Lemke H., Kirchner H., Schaadt M., Diehl V. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature. 1982 Sep 2;299(5878):65–67. doi: 10.1038/299065a0. [DOI] [PubMed] [Google Scholar]
  39. Schwarting R., Gerdes J., Dürkop H., Falini B., Pileri S., Stein H. BER-H2: a new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope. Blood. 1989 Oct;74(5):1678–1689. [PubMed] [Google Scholar]
  40. Schwartz R. H. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell. 1992 Dec 24;71(7):1065–1068. doi: 10.1016/s0092-8674(05)80055-8. [DOI] [PubMed] [Google Scholar]
  41. Smith C. A., Farrah T., Goodwin R. G. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell. 1994 Mar 25;76(6):959–962. doi: 10.1016/0092-8674(94)90372-7. [DOI] [PubMed] [Google Scholar]
  42. Smith C. A., Gruss H. J., Davis T., Anderson D., Farrah T., Baker E., Sutherland G. R., Brannan C. I., Copeland N. G., Jenkins N. A. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell. 1993 Jul 2;73(7):1349–1360. doi: 10.1016/0092-8674(93)90361-s. [DOI] [PubMed] [Google Scholar]
  43. Spriggs M. K., Armitage R. J., Strockbine L., Clifford K. N., Macduff B. M., Sato T. A., Maliszewski C. R., Fanslow W. C. Recombinant human CD40 ligand stimulates B cell proliferation and immunoglobulin E secretion. J Exp Med. 1992 Dec 1;176(6):1543–1550. doi: 10.1084/jem.176.6.1543. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Springer T. A. Adhesion receptors of the immune system. Nature. 1990 Aug 2;346(6283):425–434. doi: 10.1038/346425a0. [DOI] [PubMed] [Google Scholar]
  45. Stein H., Gerdes J., Schwab U., Lemke H., Mason D. Y., Ziegler A., Schienle W., Diehl V. Identification of Hodgkin and Sternberg-reed cells as a unique cell type derived from a newly-detected small-cell population. Int J Cancer. 1982 Oct 15;30(4):445–459. doi: 10.1002/ijc.2910300411. [DOI] [PubMed] [Google Scholar]
  46. Stein H., Mason D. Y., Gerdes J., O'Connor N., Wainscoat J., Pallesen G., Gatter K., Falini B., Delsol G., Lemke H. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood. 1985 Oct;66(4):848–858. [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES